AI Infographic

Primary Outcome

90.3%

Eradication Rate

Per-Protocol (14-THA)

Study Arms

14-THA (Winner) Rec

14 Days: Tegoprazan + Amoxicillin.
Simple Dual Therapy.

B-Quadruple Ctrl

14 Days: Esomeprazole + Bismuth + Amox + Tetra.
Complex Standard.

10-THA Fail

10 Days: Tegoprazan + Amoxicillin.
Insufficient Duration.

Efficacy Analysis (Per-Protocol)

14-THA is statistically non-inferior to B-Quadruple (p > 0.05).

Safety Profile

Adverse Events (14-THA) 15.2%

Adverse Events (B-Quad) 20.6%

While not statistically significant, the Dual Therapy showed a numerically lower incidence of adverse events compared to the Quadruple regimen.

Adherence

Compliance Rate >93%

High adherence across all groups.

Clinical Takeaway: The 14-Day Tegoprazan-Amoxicillin Dual Therapy is recommended as a preferred first-line treatment. It offers high eradication rates comparable to Bismuth Quadruple therapy but with a simplified drug regimen. (Avoid the 10-day regimen).

Source: Y. Fan, C. Li, W. Zhang, et al., “Fourteen-and Ten-Day Tegoprazan–Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Eradication—A Noninferiority, Multicenter, Randomized Controlled Trial,” Journal of Gastroenterology and Hepatology (2025): 1–10, https://doi.org/10.1111/jgh.70180.

Abbreviations: RCT — randomized controlled trial; PP — per-protocol; THA — Tegoprazan + Amoxicillin; B-Quad(ruple) — bismuth quadruple therapy; Amox — amoxicillin; Tetra — tetracycline; AE — adverse events; N — sample size; p — p-value.

group	14-THA (Dual)
rate	90.3